DIAPH3 predicts survival of patients with <i>MGMT</i>-methylated glioblastoma

<h3>Background</h3><p dir="ltr">Glioblastoma is one of the most aggressive primary brain tumors, with a poor outcome despite multimodal treatment. Methylation of the <i>MGMT</i> promoter, which predicts the response to temozolomide, is a well-established progn...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Georges Chehade (18007084) (author)
مؤلفون آخرون:	Nady El Hajj (686554) (author), Mohamed Aittaleb (18007087) (author), Maisa I. Alkailani (15070764) (author), Yosra Bejaoui (8552574) (author), Asma Mahdi (18007090) (author), Arwa A. H. Aldaalis (18007093) (author), Michael Verbiest (532371) (author), Julie Lelotte (9223075) (author), Nuria Ruiz-Reig (14434026) (author), Irene Durá (18007096) (author), Christian Raftopoulos (843696) (author), Nicolas Tajeddine (18007099) (author), Fadel Tissir (245153) (author)
منشور في:	2024
الموضوعات:	Biomedical and clinical sciences Clinical sciences Neurosciences Oncology and carcinogenesis diaphanous formin glioblastoma mDia2 O(6)-methylguanine-DNA methyltransferase MGMT methylation survival The Cancer Genome Atlas
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

DIAPH3 predicts survival of patients with <i>MGMT</i>-methylated glioblastoma

مواد مشابهة